International Business Operation

15
countries

85
Generics

215
Brands

Click for details

Close

Bangladesh's pharmaceutical industry, particularly the export of pharmaceuticals, is associated with aristocracy, prestige, and glory. This sector is vital to our developing economy. Bangladesh began exporting pharmaceuticals in 1987. It will now grow to be a massive tree and is anticipated to cost $1 billion USD by 2025. The pharmaceutical industry has expanded significantly over the last three decades, making it one of the most capital-intensive white-collar industries in the nation today. Bangladesh has been benefiting from comparative advantages in the sector because of TRIPS, a favorable WTO legal framework, and a sufficient supply of inexpensive, skilled labor.

Delta Pharma Limited is a WHO cGMP compliant and ISO 9001:2015 certified manufacturer of Generic formulations of Pharmaceuticals. Delta Pharma Limited is recognized as a model of trust and efficiency in Bangladesh and around the world. It understands the healthcare needs of patients and are always searching to find new and innovative ways to serve the consumers worldwide. Each member gives a sincere drive to comprehend the healthcare demands and channel all the strengths to provide superior quality medicine at affordable prices maintaining the delivery schedule commitments. The pledge to quality is reflected through the accreditations from stringent pharmaceutical regulatory authorities such as Philippines FDA, NAFDAC Nigeria, PPB Kenya, MOH Cambodia and FDA Afghanistan. Delta Pharma believes that the pharmaceutical business is built solely on the blocks of trust and it takes perseverance for a pharmaceutical business entity to earn the trust of the people. The testament of this belief is given by the presence of more than 10 countries. The company exports a diverse range of generic products to Philippines, Myanmar, Cambodia, Sri Lanka, Sudan, Nigeria, Vietnam, Afghanistan, Maldives, Guatemala and others.

Our establishment of efficient supply chain management and high-quality regulatory documentation serves as the primary impetus behind fulfilling the need for expanding into international markets.

To take advantage of new sales and growth prospects, we are concentrating on expanding into emerging areas with expanding healthcare demands, such as regions of Asia, Africa, and Latin America. To address the unique healthcare requirements and preferences of many areas and nations, we are also concentrating on market techniques. We also places a strong focus on exporting specialized drugs with larger profit margins, such as novel antibiotics and antihypertensives, in order to increase income streams.

Additionally, we work together with distributors and regional pharmaceutical businesses in our target areas to bolster our market presence. In regulated marketplaces, registering pharmaceuticals necessitates highly standardized documentation. In order to fulfil their demands, a highly advanced and certified manufacturing facility, a standardized production process, appropriate quality control, and most importantly, highly qualified personnel are needed. Delta has been working on that aim and has made significant progress towards meeting the requirements bit by bit. However, given the current state of the global economic crisis, we are paying closer attention to LDCs, and we will progressively examine moderately regulated nations next to each other. We intend to expand our export market by entering into contract manufacturing agreements with developed country businesses.

CHALLENGES TO EXPAND THE GLOBAL BUSINESS OF DELTA PHARMA:

• The global pharmaceutical market is highly competitive with many established players. Companies may differentiate their products to gain market share. We should open our eyes before entry in global market.
• Meeting the diverse and stringent regulatory requirements of different countries and regions can be complex and time consuming. We must ensure that our products will meet the efficacy and quality standard and obtain necessary approvals and certification from foreign regulatory authorities.
• Many countries implement price controls on pharmaceutical products which can impact our profitability. So, efficient negotiation is more important to win this battle.
• Understanding and adopting to local cultural preferences, healthcare practices and market dynamics is crucial for successful global market entry. What works in one country may not work to another. We have to act accordingly.
• Political and economic instability for exporting countries can pose risks to investments and operations. Currently dollar fluctuation is a global crisis. We need to focus on it carefully.
• Complex and lengthy registration procedures and regulatory formalities in export destinations is another challenge, which we have to deal with proper care and efficiency.
• Difficulty in finding reliable distributors and agents overseas especially in African market.
• Restrictions on transferring funds for overseas sales and market promotion is another challenge.